Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer  Findings suggest broader utility in cancer supportive care, building on interim

ARTL

Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy

Artelo Advances ART27.13 prospects; CAReS signals potential in cancer care

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer  Findings suggest broader utility in cancer supportive care, building on interim</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Artelo Biosciences disclosed nonclinical ART27.13 data showing reduced chemotherapy-induced neuropathic pain in a paclitaxel model, expanding potential oncology supportive-care use. Interim CAReS Phase 2 results also show weight gain, lean body mass increases, and higher activity, underscoring ART27.13&#039;s broader applicability beyond anorexia and cachexia. Ongoing CAReS evaluation may yield further clinically meaningful readouts and catalysts.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Artelo reports nonclinical ART27.13 reduces neuropathic pain in paclitaxel model; supports cancer supportive care.</li><li>CAReS interim results show weight gain, lean mass gains, higher activity; no approved CACS options.</li><li>Data suggest ART27.13 may address chemotherapy-induced neuropathy, broadening cancer supportive care use.</li><li>80% of advanced cancer patients experience cachexia; no FDA-approved therapies exist.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Artelo Biosciences, Inc. (ARTL)</strong>: Lead program ART27.13; nonclinical neuropathic pain data and CAReS Phase 2 results could drive near-term upside.</li><li><strong>AstraZeneca plc (AZN)</strong>: Original developer of ART27.13; contextual backdrop for the program and potential licensing discussions.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Industry News: details early-stage trial data and neuroscience-led supportive-care opportunities; frames near-term catalysts for ART27.13 and potential partnerships.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Nonclinical ART27.13 neuropathic pain data may expand oncology supportive-care use.</li><li>CAReS interim results show weight/lean mass gains and activity increases; potential for broader appeal.</li><li>No FDA-approved treatments for cancer anorexia-cachexia syndrome; positive data could attract partnerships.</li><li>CAReS trial details (ISRCTN15607817) and dosing up to 1300 µg/day provide near-term milestones.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>ART27.13 is a peripherally restricted CB1/CB2 agonist; administered orally once daily; in CAReS Phase 2.</li><li>Nonclinical paclitaxel-induced peripheral neuropathy model showed reduced pain behaviors with ART27.13.</li><li>CAReS interim results: weight gain and lean body mass improvements; activity increases at all doses; top dose &gt;6% weight gain vs 5% placebo loss.</li><li>Doses in CAReS up to 1300 µg/day; favorable safety profile reported.</li><li>CACS affects up to 80% of patients with advanced malignancies; no FDA-approved treatments.</li><li>CAReS ISRCTN registry: ISRCTN15607817; interim results presented at ICRS 2026 in Dijon, France.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish near-term on ART27.13; catalysts likely from CAReS interim readouts in coming months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="center"><em>Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer</em></p>  <p align="center"><em>Findings suggest broader utility in cancer supportive care, building on interim findings from CAReS Phase 2 clinical study which demonstrated improvements in body weight, lean body mass and activity levels</em></p>  <p>SOLANA BEACH, Calif., July  13, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=I6eowsY9J-S8bqo9bqxZKVX5yobY4mKipHK-y_FcJmAwTcuBeiAClAms-NlYyYug-njptLOIp3aLRCmn8PxD_B2_DDGh_ExMacHFv4d3_1eL5q3kvgGj2f-T_VuVCrx4IsaLh9zQCFmUFKtHQuMAsbQd_viKIY8PceQPkmlF0J3T_CDwK23_OKoX9eMyWfSoz98ixeo-bheWMQ7_3QPJz-xB-obyl-XfyPFnOU31Z4OkUi21amVswyyJlrdWduPaYWbJXYViccGkFx4btHrxdA==" rel="nofollow" target="_blank">Artelo Biosciences, Inc.</a><strong> (Nasdaq: ARTL) </strong>("Artelo" or the "Company), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced promising results from nonclinical studies in neuropathic pain with ART27.13, the Company&#39;s proprietary peripherally restricted cannabinoid receptor agonist, currently in Phase 2 clinical development evaluating patients experiencing cancer-related anorexia cachexia syndrome (CACS).</p>  <p>To determine whether ART27.13 has the potential to address neuropathic pain in cancer patients, researchers at Artelo investigated its proprietary dual cannabinoid agonist in a nonclinical model of paclitaxel-induced peripheral neuropathy, a debilitating side effect that affects approximately 60%-80% of patients receiving paclitaxel<sup>1</sup>.</p>  <p>Results demonstrated that repeated dosing with ART27.13 reduced neuropathic pain-associated behaviors (mechanical allodynia and thermal hyperalgesia) in both male and female paclitaxel-treated animals, supporting further exploration of the compound in oncology supportive care settings.</p>  <p>"Chemotherapy-induced peripheral neuropathy can significantly affect patient quality of life and may limit cancer treatment adherence," said George Warren, Ph.D., lead scientist at Artelo Biosciences and presenter of the pain study results at the International Cannabinoid Research Society (ICRS) 2026 Annual Symposium recently held in Dijon, France. "The results observed in this model suggest that ART27.13 may have broader applications in cancer supportive care beyond CACS. We have incorporated several pain endpoints into the Cancer Appetite Recovery Study (CAReS) trial and, we look forward to reviewing these upon study completion to determine if the analgesic potential of ART27.13 in a cancer setting translates into the clinic."</p>  <p>CACS affects up to 80% of patients with advanced malignancies<sup>2</sup> and is associated with reduced treatment tolerance, diminished physical functioning and poorer clinical outcomes. There are currently no FDA-approved treatment options available for CACS. ART27.13 is being evaluated in the CAReS and interim results also presented at ICRS demonstrated encouraging trends across several clinically meaningful endpoints, including improvements in body weight and lean body mass, increased activity levels, and favorable safety profile at doses up to 1300 µg/day.</p>  <p>"Interim CAReS results, and the new data in neuropathic pain, suggests peripheral cannabinoid receptor modulation may influence multiple pathways associated with appetite regulation, metabolism, body composition and symptom management, particularly chemotherapy-induced neuropathic pain, in patients with cancer," said Professor Saoirse E. O&#39;Sullivan, Vice President of Translational Science at Artelo Biosciences and presenter of the interim results from CAReS. "Importantly, the supportive care opportunity for ART27.13 may extend beyond appetite stimulation and weight maintenance, as demonstrated by additional research presented at ICRS."</p>  <p>"Despite its significant impact on patient outcomes and quality of life, CACS remains an area of substantial unmet medical need with limited therapeutic options available to patients and physicians," continued Professor O’Sullivan. "The trends observed in body composition and activity measures from CAReS are particularly encouraging given the profound impact these factors can have on patients living with CACS."</p>  <ol style="list-style-type:decimal;"><li><a href="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1762734/full?utm_source" rel="nofollow" target="_blank">https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1762734/full?utm_source</a></li><li><a href="https://www.cancer.gov/about-cancer/treatment/research/cachexia?utm_source=" rel="nofollow" target="_blank">https://www.cancer.gov/about-cancer/treatment/research/cachexia?utm_source=</a></li></ol>  <p><strong>About ART27.13</strong><br></br>ART27.13 is a novel cannabinoid receptor agonist being developed as supportive care for people with cancer experiencing anorexia and cachexia. Administered orally once daily, the treatment goals with ART27.13 are to improve appetite, body weight, and activity levels while preserving muscle and elevating quality of life. Initially developed by AstraZeneca plc, ART27.13 selectively targets peripheral cannabinoid (CB<sub>1</sub> and CB<sub>2</sub>) receptors to avoid the CNS side effects typically associated with some cannabinoids. While exhibiting a favorable safety profile at all doses in the CAReS trial, interim analysis from the blinded and randomized Phase 2 study demonstrated a mean weight gain of over 6% for participants that received the top dose of ART27.13 compared to a 5% loss in the placebo group. A weight loss of more than 5% can predict a poor outcome for cancer patients and a lower response to therapy. Currently, there areno FDA approved treatments for cancer anorexia cachexia syndrome.</p>  <p><strong>About CAReS</strong><br></br>The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of the Company’s lead clinical program, ART27.13, in people with cancer experiencing anorexia and weight loss. Cancer-related anorexia, or the lack or loss of appetite in the person with cancer, may result from the cancer and/or its treatment with radiation or chemotherapy. It is common for people with cancer to lose weight. Anorexia and the resulting weight loss can affect a patient’s health, often weakening their immune system and causing discomfort and dehydration. Interim data from the Phase 2 portion of CAReS showed improvements in lean body mass, weight gain, and activity among patients treated with all doses of ART27.13, particularly at the highest dose, compared to the participants administered placebo. (ISRCTN registry: <a href="https://www.globenewswire.com/Tracker?data=ayyMZvBOADWFJ_FSS4vP8ynvHEb1q39evqD3d1azQe9AO_ypEXuT7rUukp4ulRBh0aM3n4KfAtY6x-z4H_uv3HgJFwFxpeCesxae6Ua1inTC3B9u0Wq06YqmK9Be2VCkwQoyyw_nuiy1S9DszyP5vY3FS6teWFCfP_mHnfgJzfiEkLf0eLAG79Zwjjtnxs941pnuA0oCVV8Wnr-839qk6BtNfUmqBxJPIondipWpu8k015zlcW0-8Ly7_au2XFheF9jFG6jYZySSupORMjjykgyoo9tpgVozDtpZ8Ru95xGTEogHqzQlWmDoQIqYIyS0edb3nBMs6-XOJbDl_1klB95QH4e5E4Xmw5Lj2R3xlrGEe5XY9ALHzBnmr3LRjLUsvUkbj54mgnApIp3HcnTG10Dhi92QfBM-PAN7kglpWTWvmmsEdJNsZRC7TDEnUYG1WaT4XhTeZQ6l4Su-wTRIcfRpjeNaK5UcApAO1_5j-vnuAgN9Pb68BCBk7AGiFy5Bdy4fhw-4ryS4yla-2Cn-wHUMRBYRNLXETIXQxB6U5yz2kXSlUrM_bcTZU8QPskdgyS7FCYVfnrAM8Wm8DqSWOLP2PDnJ5NITY4pgp6ZiCepskCNrsP7KfrFGgTorNna1" rel="nofollow" target="_blank">https://www.isrctn.com/ISRCTN15607817</a>)</p>  <p><strong>About Artelo Biosciences</strong><br></br>Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, and commercial practices to maximize stakeholder value. More information is available at <a href="https://www.globenewswire.com/Tracker?data=ODrVrq6CmU35elgem7Zr5WIpnWgcAz0-nDnrB6e90PaZ2yPV9teE-LyWRMXfgwWJppCtMee7DpAikdYvKtMtN76gs4b209t4R8T1iqd2WVqlyWNcaiKAOtPtq7hnm7JUOFBQ4OcMlGKTRgtYDKYdVRhsS_8zu-3h8cemFs2JEbyQBMBQfXFJgEPLI77tMEcfO6pDS9Pep1l60F-6geLfRFJoZQnkOxIgr_LOtrebtonl1_fkPs9JUR6uN5-A0gl0ymOYLsCgzOcmrWXd5Vod4w==" rel="nofollow" target="_blank">www.artelobio.com</a> and X: @ArteloBio.</p>  <p align="justify"><strong>Forward-Looking Statements</strong><br></br><em>This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.</em></p>  <p align="justify"><strong>Investor Relations Contact:</strong><br></br>Crescendo Communications, LLC<br></br>Tel: 212-671-1020<br></br>Email: ARTL@crescendo-ir.com</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc2MDU1OCM3NzAxMzUwIzIxODc1NzA="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/Njg2NWU1MjMtY2IwZS00MzdlLWFmY2MtYWFhZDdlN2E0YTkxLTExOTkxMjMtMjAyNi0wNy0xMy1lbg==/tiny/Artelo-Biosciences.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/460502d7-b0d3-43d8-a15a-5b2bb963bbbb"><img src="https://ml.globenewswire.com/media/460502d7-b0d3-43d8-a15a-5b2bb963bbbb/small/artelo-jpg.jpg" border="0" width="150" height="66" alt="Primary Logo"></img></a></p>

Artelo Biosciences disclosed nonclinical ART27.13 data showing reduced chemotherapy-induced neuropathic pain in a paclitaxel model, expanding potential oncology supportive-care use. Interim CAReS Phase 2 results also show weight gain, lean body mass increases, and higher activity, underscoring ART27.13's broader applicability beyond anorexia and cachexia. Ongoing CAReS evaluation may yield further clinically meaningful readouts and catalysts.

Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Industry News

Related News